Latest news with #CreativeBiolabs
Associated Press
5 days ago
- Health
- Associated Press
Creative Biolabs Debuts Platforms for Smarter T Cell Stimulation
Creative Biolabs delivers tailored T cell activation solutions using hydrogel matrices, DNA scaffolds, and synthetic systems for precise and efficient immune modulation. Creative Biolabs, the global pioneer in immunotherapy, has developed novel artificial T cell-stimulating platforms —like hydrogel matrices, DNA scaffolds, and synthetic systems—to enhance CAR-T, TCR-T, and adoptive cell therapy research in oncology and immunology. Activation of T cells is also a key issue in cancer immunotherapy, especially as researchers seek more physiologically relevant conditions in which to optimize cell growth, survival, and activity. Creative Biolabs' artificial platforms replicate the most critical aspects of the original lymphoid microenvironment—enabling antigen-specific stimulation and controlled co-signal presentation that reduce activation-induced death and provide for long-lasting immunity. One of the newly announced technologies is a hydrogel-based artificial T cell-stimulating platform, which includes tunable formats such as artificial T cell-stimulating matrices (aTM), artificial lymph node scaffolds (aLN), and immunomodulatory macroporous hydrogels. The platforms enable the possibility of accurately modulating the stiffness of the matrix and biochemical ligand density, triggering localized immune activation with a low off-target effect. Complementing these is the DNA-based platform, which uses self-assembled DNA scaffolds to mimic dendritic cell architectures. With tunable conjugation protein ratios and high surface-to-volume efficiency, researchers can modulate multi-signal stimulation profiles to fit therapeutic design parameters. The platform further improves functional antibody display and allows for scalable stimulation approaches. 'Our tools bridge the gap between engineering precision and biological complexity,' said a Creative Biolabs senior R&D director. 'By simulating the critical immunological signals with synthetic and bioinspired materials, we're empowering scientists to accelerate discovery and improve cell product quality.' In addition to proprietary technology, Creative Biolabs offers end-to-end service customization in processes like DNA scaffold design, molecular engineering, protein functionalization, and in vitro / in vivo testing. Each workflow is supported by GLP-grade quality systems and high-throughput facilities to offer reproducibility and data integrity during the experimental stages. Customers are not only offered cutting-edge platforms but also professional advice and flexible project delivery. Creative Biolabs' team of specialists ranges from immunology, synthetic biology, and materials science to offer cross-functional support that is tailored to achieve every research goal. With applications from antigen-specific T cell screening to potency optimization and the development of novel therapeutics, artificial stimulation platforms hold the promise of transforming the evaluation and scaling of cell therapies. Creative Biolabs is leading innovation in this space, committed to enabling global partners to unlock the full potential of immune-based therapeutics. For additional information or to obtain a custom quote, visit About Creative Biolabs Creative Biolabs is a leader in immunotherapy, delivering customized artificial T cell-activating platforms for CAR-T and TCR-T studies. Their hydrogel, DNA, and synthetic platforms replicate critical immune signals, optimize activation efficiency, and facilitate scalable therapies—uniting engineering accuracy and biological sophistication to propel global cell therapy innovation. Media Contact Company Name: Creative Biolabs Contact Person: Candy Swift Email: Send Email City: Shirley State: New York 11967 Country: United States Website: Press Release Distributed by To view the original version on ABNewswire visit: Creative Biolabs Debuts Platforms for Smarter T Cell Stimulation
Associated Press
25-02-2025
- Business
- Associated Press
Efficient Delivery Solutions from Creative Biolabs
With the enabling platforms and technologies at its disposal, Creative Biolabs is poised to address critical challenges in gene delivery and targeted therapy. SHIRLEY, NY, UNITED STATES, February 25, 2025 / / -- Gene therapy has tremendous promise in curing diseases that have been declared untreatable, but the delivery systems must be effective and precise for success. Creative Biolabs is proud to announce that, being a global biotechnology and life sciences leader, it has developed state-of-the-art gene therapy solutions to fast-track the development of next-generation therapeutics. This technology empower scientists and pharmaceutical companies with powerful tools to enhance research efficacy and reduce off-target effects. Creative Biolabs' lipid nanoparticle platform is designed to encapsulate and deliver nucleic acids (such as siRNA, mRNA, or DNA) with high efficiency. The LNP can be optimized for maximum stability, biocompatibility, and tissue-specific targeting and are amenable to a wide range of gene therapy development research. Synthesis Service of ARCs and AOCs Creative Biolabs is also expanding its service portfolio to include antibody-siRNA conjugates (ARCs) and antibody-oligonucleotide conjugates (AOCs), two powerful approaches combining the targeting specificity of antibodies with the silencing capabilities of RNA molecules. 'We have devised several ways to synthesize ARCs and AOCs. For instance, we can conjugate siRNA onto antibodies using non-covalent interactions or covalent binding to lysine or cysteine residues that are positioned within the antibody structure. This possible methodology has the power to treat multiple ailments by utilizing both the antibodies' specific identification and the gene-silencing abilities of siRNA,' one scientist explained. GalNAc-siRNA Therapeutics Development To further enable the growing demand for RNA-based therapies, Creative Biolabs is also offering custom GalNAc (N-acetylgalactosamine) conjugation services to enhance the tissue-specific delivery of RNAi therapeutics. Scientists at this firm have great experience in this area, having the capacity to introduce chemical modifications that would boost the stabilization and activities of these GalNAc-siRNA conjugates. 'We are excited to introduce these cutting-edge solutions, which represent a significant advancement in RNA delivery and targeting technology,' said the manager of Creative Biolabs. 'Working with us, researchers can obtain breakthroughs faster and overcome delivery challenges.' As a leading provider in the biotechnology field, Creative Biolabs is repeatedly pushing the transition of gene therapy and RNA-based technology. The newly launched services further show their determination to serve their clients in the latest development of gene therapy. To learn more, please go to About Creative Biolabs Creative Biolabs is a trusted partner in the biotechnology and life sciences industry, offering one-stop solutions and services to support the discovery and development of new gene therapies and RNA-based therapies. Dedicated to quality and innovation, the company serves customers around the world in their pursuit of groundbreaking discoveries. Candy Swift Creative Biolabs +1 631-830-6441 Legal Disclaimer:
